Financial Performance - Q2 2025 revenue was $47.4 million[21] - Nucleic Acid Production (NAP) revenue was $31.1 million, representing 66% of total revenue[37] - Biologics Safety Testing (BST) revenue was $16.3 million, accounting for 34% of total revenue[37] - The company reported a GAAP net loss of $69.8 million, which includes a $30.4 million non-cash goodwill impairment charge[27] - Adjusted EBITDA was negative $10.4 million, with an adjusted EBITDA margin of -22%[27] - Basic and Diluted EPS were both negative $0.27, while Adjusted EPS was negative $0.08[29] Balance Sheet and Cash Flow - Cash used in operations during Q2 2025 was $10.3 million[33] - The company's cash position is $270 million, with long-term gross debt of $297 million, resulting in net cash of negative $27 million[33] Strategic Initiatives - A restructuring plan is in place, targeting more than $50 million in annual cost savings[15, 39] - The company aims to return to positive adjusted EBITDA in the second half of 2026[15] - The company is targeting positive free cash flow in the second half of 2026[15]

Company Overview - AlTi Global manages or advises on approximately $97 billion in combined assets[4] - The company boasts a client retention rate of 96% since 2021[11] - Approximately 59% of Wealth Management AUM/AUA is from the U S, while 41% is from non-U S sources[11] Financial Performance (Q2 2025) - Total revenue reached $53 million, a 7% increase compared to Q2 2024's $49 5 million[71] - Wealth Management and Capital Solutions (WM & CS) revenue was $52 million, with management fees at $49 million, up 8% and 6% year-over-year, respectively[70] - AUM/AUA increased by 35% year-over-year to $97 2 billion[71] Strategic Initiatives - AlTi Global finalized an expense optimization plan using Zero-Based-Budgeting (ZBB), expecting $20 million in annual gross savings over the next two years[70] - The company completed the acquisition of Kontora, a Hamburg-based MFO with $16 billion in AUA/AUM, on April 30, 2025[70] - Strategic investments from Allianz X and CWC provide up to $450 million to fuel AlTi's M&A pipeline and accelerate international expansion[15]

Q2 2025 Results August 11th, 2025 Green Dot Corporation Safe Harbor Statement This presentation contains forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, among other things, statements regarding Green Dot's business and pipeline momentum, revenue and division trends, timing and impact of partner launches and 2025 guidance and outlook, and other future events that involve risks and uncertainties. Act ...

Second Quarter 2025 Earnings Call Supplemental Slides John Sabino, Chief Executive Officer John Collins, Chief Financial Officer and Chief Operating Officer August 11, 2025 Disclaimer This presentation as well as the associated earnings release and earnings call contain and will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements ...

Second Quarter 2025 Earnings August 11, 2025 Important notice Unless the context otherwise provides, "we," "us," "our," "Bakkt" and like terms refer to Bakkt Holdings, Inc. and its subsidiaries. FORWARD-LOOKING STATEMENTS This presentation and accompanying oral presentation contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include, but are not limited to, the Co ...

This presentation contains estimates and other statistical data made by independent parties and us relating to data about ourindustry. This involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. Please see the Appendix for a statement on risks and uncertainties. HI ...

SECOND QUARTER 2025 This communication contains "forward-looking statements" that are not historical facts, and involve risks and uncertainties that could cause actual results of AST SpaceMobile to differ materially from those expected and projected. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes," "estimates," "anticipates," "expects," "intends," "plans," "may," "will," "would," "potential," "projects," "predicts," "continue," or ...

Second Quarter 2025 August 11, 2025 Important Information Important Information and Where to Find it In connection with the Transaction, WOW! will file with the SEC a proxy statement on Schedule 14A, the definitive version of which will be sent or provided to Company stockholders. WOW!, affiliates of WOW! and affiliates of each of DigitalBridge and Crestview intend to jointly file a transaction statement on Schedule 13E-3 (the "Schedule 13E-3") with the SEC. WOW! may also file other documents with the SEC r ...

Financial Performance - Oklo reported a loss from operations of $28 million for Q2 2025 [59] - The loss before income taxes for Q2 2025 was $243 million [59] - Cash used in operating activities YTD 2025 totaled $3071 million [60] - Oklo's cash and marketable securities amounted to approximately $683 million as of June 30, 2025 [29] Licensing and Regulatory Progress - The NRC accepted Oklo's licensed operator topical report for review [29] - Oklo completed Phase I of the NRC pre-application readiness assessment for the Aurora-INL combined license application (COLA) [29, 32] - Oklo is targeting submission for Phase I of Aurora-INL's COLA early Q4 2025 [32] Fuel Strategy and Supply - Oklo secured 5 metric tons of HALEU fuel from the U S Department of Energy in 2019 [33] - Oklo is collaborating with Hexium to expand the commercial HALEU supply [29, 33] - Oklo's fast reactors can utilize spent nuclear waste recovered by Oklo's nuclear fuel recycling technology [33] Partnerships and Project Execution - Kiewit was selected as the lead constructor for the Aurora-INL project [29, 43] - Oklo and Korea Hydro & Nuclear Power (KHNP) signed a collaboration agreement [29, 46] - Oklo and Vertiv partnered to advance solutions for U S data centers [29, 49]

Financial Performance - Total operating expenses increased to $17596 thousand in Q2 2025 from $10471 thousand in Q2 2024[13] - Research and Development (R&D) expenses increased to $11049 thousand in Q2 2025 from $9078 thousand in Q2 2024[13] - General and Administrative (G&A) expenses increased significantly to $6547 thousand in Q2 2025 from $1393 thousand in Q2 2024[13] - Net loss increased to $16320 thousand in Q2 2025 from $9494 thousand in Q2 2024[13] - The company had $1492 million in cash, liquidity fund, time deposits and U S treasury bills[13] - The company raised approximately $15 million in gross proceeds in a registered direct offering on August 8, 2025[13] Pipeline and Clinical Trials - Belite Bio is conducting a Phase 3, 2-year global trial ("PHOENIX" Study) for Stargardt Disease (STGD1) with completed enrollment of 529 subjects[10] - A Phase 3, 2-year global trial ("DRAGON" Study) is ongoing for Tinlarebant with 104 subjects aged 12-20, with completion expected in Q4 2025[10] - A Phase 2/3, 2-year global trial ("DRAGON II" Study) is ongoing for Tinlarebant with 60 subjects aged 12-20[10] Tinlarebant - Tinlarebant is a novel, once-daily oral tablet designed to reduce retinol delivery to the eye by binding to serum retinol binding protein 4 (RBP4)[11] - Belite Bio believes early intervention targeting emerging retinal pathology is the best approach to slow disease progression in STGD1 & GA[11]